References
1 Du, L., Kijlstra, A. & Yang, P. Vogt-Koyanagi-Harada disease: Novel
insights into pathophysiology, diagnosis and treatment. Prog Retin
Eye Res 52 , 84-111, doi:10.1016/j.preteyeres.2016.02.002
(2016).
2 Fonollosa, A. et al. CHARACTERIZING COVID-19-RELATED RETINAL
VASCULAR OCCLUSIONS: A Case Series and Review of the Literature.Retina 42 , 465-475, doi:10.1097/iae.0000000000003327
(2022).
3 Benito-Pascual, B. et al. Panuveitis and Optic Neuritis as a
Possible Initial Presentation of the Novel Coronavirus Disease 2019
(COVID-19). Ocul Immunol Inflamm 28 , 922-925,
doi:10.1080/09273948.2020.1792512 (2020).
4 Read, R. W. et al. Revised diagnostic criteria for
Vogt-Koyanagi-Harada disease: report of an international committee on
nomenclature. Am J Ophthalmol 131 , 647-652,
doi:10.1016/s0002-9394(01)00925-4 (2001).
5 Jiang, H. et al. Immune Phenotyping of Patients With Acute
Vogt-Koyanagi-Harada Syndrome Before and After Glucocorticoids Therapy.Front Immunol 12 , 659150, doi:10.3389/fimmu.2021.659150
(2021).
6 Joye, A. & Suhler, E. Vogt-Koyanagi-Harada disease. Curr Opin
Ophthalmol 32 , 574-582, doi:10.1097/icu.0000000000000809
(2021).
7 Hotta, Y. et al. Analysis of herpes virus group (DNA) from
cerebrospinal fluid in vogt-koyanagi-harada disease. Ocul Immunol
Inflamm 4 , 99-103, doi:10.3109/09273949609079639 (1996).
8 Bassili, S. S. et al. Detection of Epstein-Barr virus DNA by
polymerase chain reaction in the vitreous from a patient with
Vogt-Koyanagi-Harada syndrome. Retina 16 , 160-161,
doi:10.1097/00006982-199616020-00013 (1996).
9 Sugita, S., Takase, H., Kawaguchi, T., Taguchi, C. & Mochizuki, M.
Cross-reaction between tyrosinase peptides and cytomegalovirus antigen
by T cells from patients with Vogt-Koyanagi-Harada disease. Int
Ophthalmol 27 , 87-95, doi:10.1007/s10792-006-9020-y (2007).
10 Sugita, S. et al. Ocular infiltrating CD4+ T cells from
patients with Vogt-Koyanagi-Harada disease recognize human melanocyte
antigens. Invest Ophthalmol Vis Sci 47 , 2547-2554,
doi:10.1167/iovs.05-1547 (2006).
11 Liang, L. et al. TLR3 and TLR4 But not TLR2 are Involved in
Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines
Production Through Promoting the Production of Mitochondrial Reactive
Oxygen Species. Curr Mol Med 15 , 529-542,
doi:10.2174/1566524015666150731095611 (2015).
12 Wade, C. I., Earley, K. E., Justin, G. A. & Weber, M. L.
Vogt-Koyanagi-Harada disease presenting secondary to a post-infectious
Mycoplasma pneumoniae autoimmune response. Am J Ophthalmol Case
Rep 19 , 100793, doi:10.1016/j.ajoc.2020.100793 (2020).
13 Yoshino, N. et al. Vogt-Koyanagi-Harada Disease Associated
with Influenza A Virus Infection. Intern Med 57 ,
1661-1665, doi:10.2169/internalmedicine.9819-17 (2018).
14 Iwasaki, M. et al. Inflammation Triggered by SARS-CoV-2 and
ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular
Mechanisms and Implications. Inflammation 44 , 13-34,
doi:10.1007/s10753-020-01337-3 (2021).
15 Huang, C. et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet 395 ,
497-506, doi:10.1016/s0140-6736(20)30183-5 (2020).
16 Aggarwal, K. et al. Ocular surface manifestations of
coronavirus disease 2019 (COVID-19): A systematic review and
meta-analysis. PLoS One 15 , e0241661,
doi:10.1371/journal.pone.0241661 (2020).
17 Ding, X. & Chang, Q. Probable Vogt-Koyanagi-Harada Disease after
COVID-19 Vaccination: Case Report and Literature Review. Vaccines
(Basel) 10 , doi:10.3390/vaccines10050783 (2022).
18 de Queiroz Tavares Ferreira, F. et al. Possible Association
between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A
Report of Four Cases. Ocul Immunol Inflamm , 1-7,
doi:10.1080/09273948.2022.2093756 (2022).
19 Brunet de Courssou, J. B. et al. De Novo Vogt-Koyanagi-Harada
Disease following Covid-19 Vaccine: A Case Report and Literature
Overview. Ocul Immunol Inflamm 30 , 1292-1295,
doi:10.1080/09273948.2022.2028291 (2022).
20 Santamaria, A., Chang, J. & Savarain, C. SARS-CoV-2 among the
Potential Viral Triggers for Vogt-Konayagi-Harada Disease: First Case
Report and Literature Review. Ocul Immunol Inflamm 30 ,
1869-1875, doi:10.1080/09273948.2021.1966052 (2022).
21 Eatz, T. & Charles, J. H. Vogt-Koyanagi-Harada syndrome in the
setting of COVID-19 infection. Clin Case Rep 11 , e6617,
doi:10.1002/ccr3.6617 (2023).
22 Seah, I. & Agrawal, R. Can the Coronavirus Disease 2019 (COVID-19)
Affect the Eyes? A Review of Coronaviruses and Ocular Implications in
Humans and Animals. Ocul Immunol Inflamm 28 , 391-395,
doi:10.1080/09273948.2020.1738501 (2020).
23 Silva, L. T. D. et al. SARS-CoV-2 recombinant proteins
stimulate distinct cellular and humoral immune response profiles in
samples from COVID-19 convalescent patients. Clinics (Sao Paulo)76 , e3548, doi:10.6061/clinics/2021/e3548 (2021).
24 Rabaan, A. A. et al. Diverse Immunological Factors Influencing
Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination,
Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory
Responses. Pathogens 10 , doi:10.3390/pathogens10050565
(2021).